Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Good Publication Practice for Pharmaceutical Companies
- Drug companies have sometimes been criticized for their methods of developing publications as well as for their failure to publish unfavorable findings. The GPP guidelines call on companies to endeavor to publish results of all their clinical trials of marketed products. They also recommend practical steps to reduce publication bias...
- White papers 2003-05-15
- New Technique Can Reprogramme Adult Blood Cells Into Becoming Heart or Nerve Tissue
- Until recently, most scientists believed that once a cell became specialized or differentiated it was committed to a single developmental course. Thus, an adult liver cell, grown in culture, would always produce more liver cells, while a muscle cell would produce other muscle cells. However, this view is increasingly under...
- White papers 2003-07-01
- Largest Ever Study Into Male Sexual Health Reinforces Extent of Erectile Dysfunction
- The MALES study is one of the largest epidemiological surveys to investigate prevalence of ED. Unfortunately; ED is still a condition that remains under-diagnosed despite the many medical risk factors that are associated with it. The ground-breaking study also showed that among the men who reported ED, less than six...
- White papers 2004-03-09
- Rofecoxib Is Faster and More Effective Than Diclofenac Sodium in Treating Pain Following Bunionectomy Surgery
- Results of a recently completed clinical study demonstrated that rofecoxib 50 mg was significantly more effective than diclofenac sodium 100 mg in the treatment of post-operative pain associated with bunionectomy surgery the day after surgery, and patients on rofecoxib required half as much opioid medication compared to patients taking placebo...
- White papers 2004-08-23
- New Comparative Review of Osteoporosis Medications: Alendronate Provided Better Protection Against Non-Vertebral Fractures
- Results of a new analysis of clinical data for osteoporosis medications, including bisphosphonates, calcitonin, estrogen therapies and SERMS selective estrogen receptor modulators showed that alendronate provided the best protection against non-vertebral fractures. The study used an indirect method to compare six current treatments. This review showed that alendronate was substantially...
- White papers 2004-04-14
- Portfolio Therapy
- This paper discusses and provides information about technology and Portfolio Therapy for TB. It is possible to move technologies for cancer, for diabetes, for the diseases that were important, but which also had good financial-return indications. But is very hard time moving technologies for these neglected diseases. For investing in...
- White papers 2002-09-13
- << Previous
- page 1 of 1
- Next >>
Presented by American Express